Harbor Capital Advisors Inc. Buys 9,701 Shares of HealthEquity, Inc. $HQY

Key Points

• Harbor Capital Advisors Inc. increased its stake in HealthEquity, Inc. by 24.9%, owning 48,631 shares valued at approximately $5.1 million after buying an additional 9,701 shares during the second quarter.
• Analyst ratings for HealthEquity show a consensus of "Buy", with target prices set as high as $134.00 by Jefferies Financial Group, indicating strong investor confidence in the stock's potential.
• HealthEquity has experienced significant fluctuations in its stock price, with a 52-week low of $74.07 and a high of $116.65, currently trading at $91.54.

Harbor Capital Advisors Inc. increased its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 24.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,631 shares of the company's stock after acquiring an additional 9,701 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of HealthEquity worth $5,095,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Invesco Ltd. boosted its position in HealthEquity by 50.6% during the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock worth $216,171,000 after buying an additional 821,425 shares during the period. Nuveen LLC purchased a new position in shares of HealthEquity in the 1st quarter worth about $53,076,000. Price T Rowe Associates Inc. MD raised its stake in HealthEquity by 995.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company's stock valued at $56,500,000 after acquiring an additional 580,988 shares during the period. Westfield Capital Management Co. LP bought a new stake in shares of HealthEquity during the first quarter valued at about $49,787,000. Finally, Ameriprise Financial Inc. grew its holdings in shares of HealthEquity by 148.1% during the first quarter. Ameriprise Financial Inc. now owns 669,939 shares of the company's stock worth $59,203,000 after purchasing an additional 399,897 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at HealthEquity

In other news, EVP Michael Henry Fiore sold 1,794 shares of HealthEquity stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $101.73, for a total transaction of $182,503.62. Following the sale, the executive vice president directly owned 53,225 shares in the company, valued at approximately $5,414,579.25. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company's stock.

HealthEquity Stock Down 1.9%

Shares of NASDAQ:HQY traded down $1.85 during midday trading on Friday, hitting $93.74. 1,600,983 shares of the company's stock traded hands, compared to its average volume of 1,228,123. HealthEquity, Inc. has a twelve month low of $74.07 and a twelve month high of $116.65. The company has a market cap of $8.08 billion, a PE ratio of 56.81, a P/E/G ratio of 1.34 and a beta of 0.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23. The firm's fifty day moving average price is $92.85 and its two-hundred day moving average price is $93.99.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HQY shares. Barrington Research restated an "outperform" rating and set a $125.00 target price on shares of HealthEquity in a report on Friday, August 29th. Raymond James Financial reissued a "strong-buy" rating and set a $120.00 price objective (up from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. JPMorgan Chase & Co. upped their target price on HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a report on Wednesday, September 3rd. Royal Bank Of Canada increased their price target on HealthEquity from $109.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of HealthEquity from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, HealthEquity presently has a consensus rating of "Buy" and an average price target of $119.77.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.